Moderna and Merck Reveal Groundbreaking 3-Year Data Showcasing mRNA-4157 (V940) and KEYTRUDA® Efficacy in Melanoma Patients
Significant Improvement in Recurrence-Free and Distant Metastasis-Free Survival CAMBRIDGE, Mass. and RAHWAY, N.J., June 3, 2024 – Moderna, Inc. (NASDAQ:…
